GeoVax Labs (GOVX) Stock Overview
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GOVX Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
GeoVax Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.27 |
| 52 Week High | US$23.10 |
| 52 Week Low | US$0.96 |
| Beta | 3.63 |
| 1 Month Change | -38.35% |
| 3 Month Change | -9.93% |
| 1 Year Change | -89.53% |
| 3 Year Change | -99.41% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • Jun 26
GOVX: Mpox And Ebola Vaccine Refocus Will Drive Future Upside
The Analyst Price Target for GeoVax Labs has been reset from $77.50 to $10.00, with analysts highlighting the shift away from COVID-19 development and a renewed focus on the GEO-MVA smallpox/mpox and hemorrhagic fever vaccine programs as the key drivers of this updated view. Analyst Commentary Analysts covering GeoVax Labs are largely focused on how the shift away from COVID-19 and toward the GEO-MVA smallpox/mpox and hemorrhagic fever programs could affect execution risk, funding options, and the company’s ability to translate its vaccine work into commercial outcomes.Narrative Update • May 25
GOVX: Mpox And Ebola Vaccine Portfolio Will Drive Future Upside
Narrative update on GeoVax Labs Analysts now see GeoVax Labs' fair value holding at $77.50. The updated target reflects revised assumptions for revenue growth, profit margins, and a higher future P/E multiple, backed by recent research that highlights its vaccine portfolio for Mpox, Ebola, and other infectious diseases.Narrative Update • Apr 27
GOVX: Mpox Vaccine Program Will Drive Future Upside Despite Higher Execution Risk
Analysts have reduced their price target on GeoVax Labs to $77.50 from $190.83, citing a more constrained near term outlook, limited near term catalysts, tighter capital resources, and elevated execution risk around GEO-MVA. Analyst Commentary Recent research updates point to a more cautious stance on GeoVax Labs, with price targets reset and ratings pulled back as analysts reassess execution risk and funding needs around the GEO-MVA program.Recent updates
Narrative Update • Jun 26
GOVX: Mpox And Ebola Vaccine Refocus Will Drive Future Upside
The Analyst Price Target for GeoVax Labs has been reset from $77.50 to $10.00, with analysts highlighting the shift away from COVID-19 development and a renewed focus on the GEO-MVA smallpox/mpox and hemorrhagic fever vaccine programs as the key drivers of this updated view. Analyst Commentary Analysts covering GeoVax Labs are largely focused on how the shift away from COVID-19 and toward the GEO-MVA smallpox/mpox and hemorrhagic fever programs could affect execution risk, funding options, and the company’s ability to translate its vaccine work into commercial outcomes.Narrative Update • May 25
GOVX: Mpox And Ebola Vaccine Portfolio Will Drive Future Upside
Narrative update on GeoVax Labs Analysts now see GeoVax Labs' fair value holding at $77.50. The updated target reflects revised assumptions for revenue growth, profit margins, and a higher future P/E multiple, backed by recent research that highlights its vaccine portfolio for Mpox, Ebola, and other infectious diseases.Narrative Update • Apr 27
GOVX: Mpox Vaccine Program Will Drive Future Upside Despite Higher Execution Risk
Analysts have reduced their price target on GeoVax Labs to $77.50 from $190.83, citing a more constrained near term outlook, limited near term catalysts, tighter capital resources, and elevated execution risk around GEO-MVA. Analyst Commentary Recent research updates point to a more cautious stance on GeoVax Labs, with price targets reset and ratings pulled back as analysts reassess execution risk and funding needs around the GEO-MVA program.Narrative Update • Apr 13
GOVX: Mpox Vaccine Progress Will Support Upside Despite Hold Rating
Narrative Update Analysts have reduced their price target for GeoVax Labs by about $80. They reflect a more cautious stance as they point to a more constrained near term outlook with limited catalysts and tighter capital resources, even as the company continues to progress GEO-MVA with elevated execution risk.Narrative Update • Mar 29
GOVX: Mpox Vaccine Progress Will Offset Hold Rating And Funding Constraints
Analysts have trimmed their fair value estimate for GeoVax Labs to $270.83, reflecting a slightly lower discount rate, a smaller but still very large projected revenue growth figure, and a higher profit margin assumption. They also flagged a more constrained near term outlook with limited catalysts and tighter capital resources following the recent downgrade to Hold.Narrative Update • Mar 11
GOVX: Mpox Vaccine Execution Risks Will Set Up Future Upside Potential
Analysts have trimmed their price target on GeoVax Labs, with the updated fair value estimate holding at about $270.83 per share, as they flag a more constrained near term outlook, limited catalysts, and tighter capital resources around the GEO-MVA program, which they see as raising execution risk. Analyst Commentary Recent commentary points to a more cautious stance on GeoVax Labs, with the focus shifting to execution and funding rather than headline upside.Narrative Update • Feb 24
GOVX: Mpox Vaccine Progress And Capital Raises Will Support Future Upside
Analysts have raised their fair value estimate for GeoVax Labs from about $204.63 to roughly $270.83, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E, despite a more constrained near term outlook and higher execution risk highlighted in recent research. Analyst Commentary Recent research has become more cautious on GeoVax Labs, even as fair value estimates have moved higher.Narrative Update • Feb 10
GOVX: Reverse Split And Recent Capital Raises Will Support Future Upside
Analysts have kept their fair value target for GeoVax Labs steady at US$204.63, with only minor tweaks to inputs like the discount rate and expected future P/E to reflect updated modeling assumptions rather than a change in conviction. What's in the News GeoVax filed a Certificate of Amendment on January 9, 2026 to implement a 1 for 25 reverse stock split, combining every 25 existing common shares into 1 new common share, with stockholder ownership percentages and voting power described as substantially unchanged apart from rounding adjustments (company filing).Narrative Update • Jan 26
GOVX: Reverse Split And Capital Raises Will Support Future Vaccine Upside
Analysts have trimmed their price target on GeoVax Labs from US$240.63 to US$204.63, citing updated assumptions for profit margins and a slightly higher discount rate, while keeping long term revenue growth expectations and future P/E views broadly aligned with prior estimates. What's in the News GeoVax Labs filed a Certificate of Amendment on January 9, 2026 to implement a 1 for 25 reverse stock split, consolidating every 25 existing common shares into one new common share while keeping stockholders' proportional ownership and voting power largely the same, aside from rounding of fractional shares (company filing).Narrative Update • Jan 12
GOVX: Late Stage Vaccine Pipeline Progress Will Drive Future Upside
Analysts have lifted their price target on GeoVax Labs from US$10.38 to US$240.63, citing updated assumptions around revenue growth of 381.98%, a profit margin of 40.57% and a forward P/E of 1.94, along with a modest adjustment to the discount rate to 7.03%. What's in the News Stockholders approved a reverse stock split authorization in November 2025, allowing a ratio between 1 for 10 and 1 for 25, with the final ratio set by the board, followed by a confirmed 1 for 25 reverse split effective January 12, 2026 (Key Developments).New Narrative • May 07
Gedeptin And GEO-MVA Trials Will Shape Vaccine And Cancer Pipelines
Progress in vaccines and strategic partnerships could drive revenue growth from commercialization and global stockpile opportunities.Analysis Article • Sep 08
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 08
GeoVax: Possible Vaccine Advancements In 2 Big Indications
GeoVax has multiple routes to go in terms of Covid-19 vaccine development; use of GEO-CM04S1 for Covid-19 in immunocompromised patients and as booster, plus GEO-CM02 as pan-coronavirus vaccine. GeoVax has the potential to possibly advance GEO-CM04S1 as a preventative Monkeypox vaccine. Successful prevention of Monkeypox in non-human primate models has been shown in peer-reviewed journal using MVA. Gedeptin is being developed for the treatment of patients with advanced head and neck cancer; MVA-VLP-MUC1 is also being advanced for the treatment of patients with solid tumors. GeoVax had $30.9 million in cash as of June 30, 2022; enough to fund its operations for at least the next 12 months. GeoVax Labs, Inc. (GOVX) is a great speculative biotech play to look into. That's because it only trades at $3 per share, but it has potential advancement for its vaccine technology in two key areas. These key areas are a Covid-19 vaccine which is ongoing in two phase 2 studies. One study is using GEO-CM04S1 as a Covid-19 vaccine and then another study using it as a booster. One key thing to note is that in terms of it being used as a Covid-19 vaccine, the phase 2 study is exploring it in immunocompromised cancer patients. This means that the biotech is specifically going after a subpopulation who may need stronger immunity against the virus. In addition, it has another shot on goal with a pan-corona virus vaccine it is working on, known as GEO-CM02. The other key area for which it is exploring the use of GEO-CM04S1 in is Monkeypox. That is, it is being explored as a prevention of Monkeypox. This vaccine technology of GEO-CM04S1 is what it is being used against other target indications such as HIV, Zika and Hemorrhagic fever viruses. The company is even expanding to cancer immunotherapy as well with its vaccine technology to develop additional shots on goal. It remains to be seen if the vaccine products ultimately work out, but I believe these two key indications could be huge value adding events. The other shots on goal in the pipeline are in early-stage testing but provide other opportunities. These are the reasons why I believe GeoVax is a great speculative biotech play to look into. Covid-19 Vaccine Possible For Patients Who Are Immunocompromised There are many Covid-19 vaccines out there and so the market is being overwhelmed with them. If that is the case, then how does GeoVax Labs hope to capitalize on advancing GEO-CM04S1 for Covid-19? There are three possibilities here. The first being that it is able to get this vaccine developed for those who are immunocompromised, especially those with cancer. The thing is that those who have cancer can't develop the antibodies necessary to fend off Covid-19. As such, they rely on T-cells only which is likely not enough. The point here is that there is an opportunity to target a specific sub-population of Covid-19 patients. This is how GeoVax can still capitalize on this market indication, without being overwhelmed. The use of GEO-CM04S1 is being explored in a phase 2 study as a primary vaccine for immunocompromised cancer patients. However, why I think this study is well powered is because it is being compared to a Pfizer (PFE)/BioNTech (BNTX) authorized messenger RNA ((mRNA)) vaccine named COMIRNATY. The primary endpoint of this phase 2 study is immune response over a 28 day period. Again, I think the opportunity here is to target-specific immunocompromised patients, especially those with cancer. The second opportunity lies in using GEO-CM04S1 as a vaccine booster in a phase 2 study. This vaccine is a synthetic modified vaccinia Ankara ((MVA))-based SARS-CoV-2 vaccine, for the prevention of Covid-19 infection. It was developed by GeoVax by putting in small pieces of SARS-CoV-2 DNA into synthetic MVA. The belief is that may be able to induce an immune response to recognize and kill off the virus. However, this study will compare the use of GEO-CM04S1 to placebo administration. The reason why I think this vaccine holds so much potential is because it's a dual approach. What do I mean by that? Well, all currently approved mRNA vaccines target the Spike protein in particular. On the other hand, GEO-CM04S1 targets two proteins. It targets both the Spike and nucleocapsid proteins. It remains to be seen if this dual targeting approach is much more adequate compared to only targeting the Spike protein alone, but there is huge potential for advancement here. Thus far, it has reported some pretty good data. For instance, back in March of 2022 is posted some results from a phase 1 study using GEO-CM04S1 in a peer-reviewed journal. The takeaway is that it was able to produce robust neutralizing antibodies and T cells against SARS-CoV-2 with no significant side effects. I think the huge promise here is that even if there eventually are additional mutations in the Spike protein, the company's dual targeting approach (targeting both Spike and nucleocapsid proteins) may still provide substantial immunity compared to those currently approved mRNA vaccines. This remains to be seen until the phase 2 results are posted, but this potential would be huge, especially for cancer patients who are really immunocompromised. The third opportunity lies with the use of GeoVax's pan-coronavirus vaccine, which is being developed as a universal vaccine for the virus. This is a good idea, because just in case the dual protein targeting approach doesn't pan out in phase 2 studies, it still has an opportunity to advance a single-dose vaccine. This single-dose vaccine being developed is known as GEO-CM02. The only problem with this program is that it is still in early development. Matter of fact, it is still being explored in preclinical studies. The purpose is to eventually get this pan-coronavirus vaccine ready for an IND filing and then subsequent human studies. Development Of A Vaccine For Monkeypox The thing is that GeoVax is doing pretty well in advancing its vaccine GEO-CM04S1 for Covid-19. However, it also has a great shot at developing a vaccine for Monkeypox as well. Why is that so? That's because the vaccine used and stockpiled for immunization against Monkeypox is MVA. As I noted above, modified vaccinia Ankara ((MVA)) is a vector also being used in all of GeoVax's vaccines targeting multiple indications such as HV, Zika, Hemorrhagic fever viruses and others. It is not quite yet a pandemic, but cases are starting to rise. As of this past Friday, there have been about 7,510 cases of Monkeypox in the United States. The majority of cases are coming from California, Florida, and New York. Globally, there has been more than 28,000 cases reported since January of this year. It's important to watch the spread of this, because it's possible that the spread could increase. There is a notion that it is not an STI and that it can be spread through close skin contact. Regardless, the rise in cases if anything should be monitored closely. Monkeypox DNA has been detected in feces and other bodily fluids. However, it is under investigation whether or not the mere presence of virus DNA found can cause a spread in these instances. The use of GeoVax's MVA-based HIV vaccine has shown to be successful in the prevention of Monkeypox in non-human primate models in a peer-reviewed publication. Preclinical studies are being done, and if the results are successful, then further studies could come about later on. The key thing is that this could open the scope for the GEO-CM04S1 MVA to be used for multiple indications. Even better, there is potential to prevent both hemorrhagic fever virus and the Monkeypox virus in a single vaccine. This has not yet been validated yet, but if it is in the coming months/year it would be a huge finding. Financials According to the 10-Q SEC Filing, GeoVax Labs Inc. had $30.9 million in cash as of June 30, 2022. The reason why it has so much cash on hand is because of a follow-on offering and private placement of common stock and warrants it had done in May of 2022. This was a registered direct and PIPE offering in which it was able to raise approximately $20 million. This is on top of the cash it had already raised back in January of 2022, which was $9.2 million. This financial transaction was a private placement of common stock and warrants. I believe that going forward the biotech will likely need to raise additional cash. It hopes to provides updates on its programs throughout 2022. If positive news is released in this 2nd half of 2022 (program/trial updates), then I expect it to raise cash immediately. Why I do believe this will be the case? That's because GeoVax notes in its 10-Q SEC filing that it believes it has enough cash to fund its operations for at least the next 12 months. It will not wait until the very end to raise cash. As such, it will likely take advantage of an immediate rise in stock price. However, such a rise will only occur if one of the ongoing studies have positive results reported. Risks To Business There are several risks that investors should be aware of before investing in GeoVax. The first risk being the Covid-1 vaccine program. That's because both the use of GEO-CM04S1 as a Covid-19 vaccine for the immunocompromised and as a booster are being evaluated in two ongoing phase 2 studies. There is no guarantee that either of these mid-stage studies will end up being successful. Even if they are successful, plus the company is able to obtain EUA for GEO-CMS04S1, there is no assurance that the vaccine will do well on the global stage. As I noted directly above in the beginning, there are many other regulatory approved vaccines, especially the most popular ones being Pfizer/BioNTech COMIRNATY and Moderna (MRNA) Spikevax. Pfizer believes that it could earn as much as $32 billion in revenue for COMIRNATY. Moderna did well for itself back in 2021, where it earned full year revenue of $18.5 billion. It already has in place the ability to earn $21 billion from Advance Purchase Agreements in 2022.Seeking Alpha • Jul 28
GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine
The shares of clinical-stage biotech GeoVax Labs (NASDAQ:GOVX) added ~16% in the morning hours Thursday after the company announced a peer-reviewed publication of an animal efficacy study on the company’s experimental vaccine for Sudan ebolavirus (SUDV). According to data posted on the Nature Partner Journals (NPJ) Vaccines, a single dosed of the vaccine, MVA-VLP-SUDV, was found to generate 100% protection in the study involving guinea pigs. A second vaccine dose further bolstered the vaccine responses of the animals, the company said, adding that all animals which received either one or two doses of MVA-VLP-SUDV developed protection against death and symptoms following a lethal dose of SUDV. “The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose,” Chief Executive of GeoVax (GOVX) Mark J. Newman explained. The company is close to completing its ongoing study for the candidate involving nonhuman primates. Benefitting from the recent monkeypox outbreak, GeoVax (GOVX) shares have climbed ~94% over the past 30 days, as shown in this graph.Analysis Article • May 24
Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Dec 27
GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
GOVX is uniquely positioned with its Phase 2 COVID-19 vaccine candidate for immunocompromised individuals. It has also started a Phase 2 trial as a booster vaccine for the general population. In addition to its GEO/COH04S1 and GEO-CM02 COVID-19 vaccine candidates, it has clinical trials on HIV and early stage candidates for a variety of infectious diseases, funded through non-dilutive sources. GOVX is valued at a $25 million market cap, but has $18 million in cash leading to just a $7 million enterprise value for its pipeline. GOVX warrants offer leveraged upside that make for a good speculative investment on a lottery ticket stock.Analysis Article • Nov 27
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Oct 03
GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program
GeoVax is developing vaccines and immunotherapies for multiple oncology and infectious disease indications. The Company has a decent cash runway for the current development pipeline. The addition of the Gedeptin program has advanced the Company’s pipeline to pivotal clinical stage.Analysis Article • Aug 14
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Shareholder Returns
| GOVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.6% | 6.1% | 0.3% |
| 1Y | -89.5% | 40.6% | 19.9% |
Return vs Industry: GOVX underperformed the US Biotechs industry which returned 40.6% over the past year.
Return vs Market: GOVX underperformed the US Market which returned 19.9% over the past year.
Price Volatility
| GOVX volatility | |
|---|---|
| GOVX Average Weekly Movement | 30.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GOVX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GOVX's weekly volatility has increased from 20% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 19 | David Dodd | www.geovax.com |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox.
GeoVax Labs, Inc. Fundamentals Summary
| GOVX fundamental statistics | |
|---|---|
| Market cap | US$4.45m |
| Earnings (TTM) | -US$21.37m |
| Revenue (TTM) | US$852.28k |
5.2x
P/S Ratio-0.2x
P/E RatioIs GOVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOVX income statement (TTM) | |
|---|---|
| Revenue | US$852.28k |
| Cost of Revenue | US$16.67m |
| Gross Profit | -US$15.82m |
| Other Expenses | US$5.55m |
| Earnings | -US$21.37m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.15 |
| Gross Margin | -1,855.97% |
| Net Profit Margin | -2,507.27% |
| Debt/Equity Ratio | 0% |
How did GOVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 22:40 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeoVax Labs, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CG Capital |
| Jason Kolbert | D. Boral Capital LLC. |
| Robert LeBoyer | NOBLE Capital Markets, Inc. |